UNION Therapeutics - About the company
UNION Therapeutics is a series B company based in Hellerup (Denmark), founded in 2013 by Morten Otto Alexander Sommer and Rasmus Vendler Toft-Kehler. It operates as a Developer of small molecule antibiotic drugs for treating bacterial infections. UNION Therapeutics has raised $57.1M in funding from European Investment Bank, with a current valuation of $*****. The company has 238 active competitors, including 84 funded and 46 that have exited. Its top competitors include companies like Spero Therapeutics, Locus Biosciences and LimmaTech Biologics.
Company Details
Developer of small molecule antibiotic drugs for treating bacterial infections. It focussed on developing therapies that overcome antibiotic resistance for the treatment of bacterial infections and related disorders. Its lead candidate, ATx201, is a small molecule topical treatment for bacterial skin infections. It also has programsATx202 and ATx401 which are topical and oral treatments for acne and C. difficile infections.
- Website
- uniontherapeutics.com
- Email ID
- *****@uniontherapeutics.com
- Phone Number
- +45 **********
- Registered Address
- Tuborg Havnevej 18 2900 Hellerup
Key Metrics
Founded Year
2013
Location
Hellerup, Denmark
Stage
Series B
Total Funding
$57.1M in 12 rounds
Latest Funding Round
Investors
Ranked
33rd among 238 active competitors
Annual Revenue
$0 - $1M as on Dec 31, 2022
Employee Count
11 as on Aug 31, 2026
Similar Companies
Legal entities associated with UNION Therapeutics
UNION Therapeutics is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
UNION therapeutics Research Services ApS CIN: 40807098 , Denmark, Active | Sep 23, 2019 | $0 - $1M (As on Dec 31, 2022) | - | |
Union Therapeutics A / S CIN: 33963750 , Denmark, Active | Oct 09, 2011 | $0 - $1M (As on Dec 31, 2017) | 26 (As on Nov 30, 2024) |
Sign up to download UNION Therapeutics' company profile
UNION Therapeutics's funding and investors
UNION Therapeutics has raised a total funding of $57.1M over 12 rounds. Its first funding round was on Aug 12, 2013. UNION Therapeutics has 9 institutional investors.
Here is the list of recent funding rounds of UNION Therapeutics:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jun 30, 2022 | 6885265 | Series B | 9560667 | 3293281 | 4734371 | 1078297 |
Feb 09, 2021 | 3373867 | Series B | 3199670 | 2087847 | 9427614 | 7227173 |
Jun 23, 2020 | 7187474 | Series A | 7398004 | 6453709 | 5260218 | 8724434 |
Access funding benchmarks and valuations. Sign up today!View details of UNION Therapeutics's funding rounds and investors
UNION Therapeutics' founders and board of directors
Founder? Claim ProfileThe founders of UNION Therapeutics are Morten Otto Alexander Sommer and Rasmus Vendler Toft-Kehler. Kim Domela Kjoller is the CEO of UNION Therapeutics.
Here are the details of UNION Therapeutics' key team members:
- Morten Otto Alexander Sommer: Founder of UNION Therapeutics. They serve on the boards of 4 companies.
- Rasmus Vendler Toft-Kehler: Co-Founder of UNION Therapeutics. They serve on the board of 1 company.
- Kim Domela Kjoller: CEO of UNION Therapeutics. They serve on the board of 1 company.Contact Info: 1 email address
UNION Therapeutics' Board of Directors
UNION Therapeutics's board has 9 active members. Morten Otto Alexander Sommer, Rasmus Vendler Toft-Kehler, Kim Domela Kjoller and Stig Lokke Pedersen are part of team and Andrew John, Gitte Pugholm Aabo, Morten Højland Boesen, Arthur Higgins and Jutta Heim are independent board members.Here is the list of UNION Therapeutics' board of directors:
Name | Type | Representing | Status | Duration |
|---|---|---|---|---|
Team | - | Current | 14y 11m | |
utjtupj | Team | - | Past | 4y 8m |
feyxvtc | Team | - | Current | 6y 7m |
kmisdpq | Team | - | Past | 3y 6m |
Independent board member | - | Current | 7y 4m | |
uoenz{j | Independent board member | - | Current | 2y 7m |
hvkztsk | Independent board member | - | Current | 4y 7m |
hpnskhi | Independent board member | - | Current | 8y 4m |
grcvldk | Independent board member | - | Current | 7y 2m |
View details of UNION Therapeutics's Founder profiles and Board Members
UNION Therapeutics' employee count trend
UNION Therapeutics has 11 employees as of Aug 26. Here is UNION Therapeutics's employee count trend over the years:
Uncover UNION Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
UNION Therapeutics's Competitors and alternates
Top competitors of UNION Therapeutics include Spero Therapeutics, Locus Biosciences and LimmaTech Biologics. Here is the list of Top 10 competitors of UNION Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Spero Therapeutics 2013, Cambridge (United States), Public | Developer of therapeutics for drug-resistant bacterial infections | $115M | 69/100 | |
2nd | Locus Biosciences 2015, Raleigh (United States), Series B | Developer of therapeutics for infectious disease and inflammatory indications | $67.3M | 64/100 | |
3rd | LimmaTech Biologics 2015, Schlieren (Switzerland), Acquired | Developing bioconjugate vaccines using glycoengineering and protein glycosylation techniques | $40M | 63/100 | |
4th |  Windward Bio 2020, Basel (Switzerland), Series B | Company develops monoclonal antibody therapeutics for immunological and respiratory diseases | $365M | 62/100 | |
5th | Paratek Pharma 1996, Boston (United States), Acquired | Developer of therapeutics for antimicrobial resistant infections | $96.5M | 61/100 | |
6th |  Everest Medicines 2017, New York City (United States), Public | Developer of drugs for the treatment of cancer | $313M | 61/100 | |
7th |  Bioversys 2008, Basel (Switzerland), Public | Developer of therapeutics for Antimicrobial Resistance | $62.5M | 61/100 | |
8th | MicuRx Pharmaceuticals 2007, Foster City (United States), Series E | Develops antibiotics against multidrug-resistant (MDR) superbug infections | $272M | 60/100 | |
9th |  RAPT 2015, San Francisco (United States), Acquired | Provider of immunology-based drug for oncology and inflammatory diseases | $199M | 59/100 | |
10th |  Vedanta Biosciences 2010, Cambridge (United States), Series E | Developer of therapeutics to treat infectious diseases | $410M | 59/100 | |
33rd | UNION Therapeutics 2013, Hellerup (Denmark), Series B | Developer of small molecule antibiotic drugs for treating bacterial infections | $57.1M | 50/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on UNION Therapeutics's competitors? Click here to see the top ones
UNION Therapeutics's Investments and acquisitions
UNION Therapeutics has made no investments or acquisitions yet.
Reports related to UNION Therapeutics
Here is the latest report on UNION Therapeutics's sector:
News related to UNION Therapeutics
Filter this listMedia has covered UNION Therapeutics for 1 event in last 1 year, It was about company updates.
•
UNION therapeutics Announces Orismilast Biomarker Modulation Profile PublicationCision•Oct 31, 2025•UNION Therapeutics
•
UNION Therapeutics presents positive Phase 2a ulcerative colitis data at ECCO.Cision•Feb 21, 2025•UNION Therapeutics
•
•
Union plans Phase III trial for atopic dermatitis after Phase IIb winPharmaceutical Technology•Sep 26, 2024•UNION Therapeutics
•
•
UNION therapeutics to present orismilast Phase 2b results in atopic dermatitis as a late-breaking oral presentation at the EADV Congress 2024Cision•Sep 20, 2024•UNION Therapeutics
•
Union Therapeutics Appoints Drug Development Leader Dr. Peter Kristensen To Its Board Of DirectorsCision•Aug 06, 2024•UNION Therapeutics, New Nordic
•
Union Therapeutics shares positive data on atopic dermatitis drug trialclinicaltrialsarena.com•Jun 12, 2024•UNION Therapeutics
•
UNION therapeutics announces successful completion of the ADESOS Phase 2b study and presentation of data at the RAVE Conference 2024PR Newswire•Jun 04, 2024•UNION Therapeutics
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about UNION Therapeutics
Explore our recently published companies
- Way - Helsinki based, 2024 founded, Seed company
- Delite - Hyderabad based, 2010 founded, Unfunded company
- Yuki - Tel Aviv based, 2023 founded, Seed company
- Hedgepointcapital.com - 2021 founded, Funding Raised company
- MicroRoboTech - Hangzhou based, 2025 founded, Series A company
- Semper Plugins - Durham based, 2011 founded, Acquired company
